IWP-2 (GMP)

CAT: 0804-HY-13912G-01Size: 10 mgDry Ice: NoHazardous: No
CAT#:0804-HY-13912G-01Size:10 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
IWP-2 (GMP) is >IWP-2 (HY-13912) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. IWP-2 is an inhibitor of Wnt processing and secretion with an IC50 of 27 nM. IWP-2 targets the membrane-bound O-acyltransferase porcupine (Porcn) and blocks Wnt ligand palmitoylation[1].
CAS Number
[686770-61-6]
UNSPSC
12352005
Hazard Statement
H302
Target
Wnt
Type
GMP Small Molecules
Related Pathways
Stem Cell/Wnt
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/iwp-2-gmp.html
Purity
99.7
Solubility
DMSO : 2 mg/mL (ultrasonic; warming)
Smiles
O=C(NC1=NC2=CC=C(C)C=C2S1)CSC3=NC(CCS4)=C4C(N3C5=CC=CC=C5)=O
Molecular Formula
C22H18N4O2S3
Molecular Weight
466.60
Precautions
P264-P270-P330-P501
References & Citations
[1]Guan J et al. Chemical reprogramming of human somatic cells to pluripotent stem cells. Nature. 2022;605 (7909) :325-331. |[2]Hamad S, et al. Generation of human induced pluripotent stem cell-derived cardiomyocytes in 2D monolayer and scalable 3D suspension bioreactor cultures with reduced batch-to-batch variations. Theranostics. 2019 Sep 25;9 (24) :7222-7238. |[3]Le MNT, et al. Auto/paracrine factors and early Wnt inhibition promote cardiomyocyte differentiation from human induced pluripotent stem cells at initial low cell density. Sci Rep. 2021 Nov 2;11 (1) :21426. |[4]Taniguchi J, et al. A synthetic DNA-binding inhibitor of SOX2 guides human induced pluripotent stem cells to differentiate into mesoderm. Nucleic Acids Res. 2017 Sep 19;45 (16) :9219-9228. |[5]Lian X, Zhang J, et al. Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/β-catenin signaling under fully defined conditions. Nat Protoc. 2013 Jan;8 (1) :162-75.
Shipping Conditions
Blue Ice
Storage Conditions
4°C, sealed storage, away from moisture
Scientific Category
GMP Small Molecules
Clinical Information
No Development Reported
Citation 01
Nat Protoc. 2024 Jul;19 (7) :1911-1939.|ACS Comb Sci. 2019 Dec 9;21 (12) :805-816.|Adv Mater. 2021 Dec;33 (49) :e2104829.|Autoimmunity. 2023 Dec;56 (1) :2182741.|Biocell. 2025 Feb 28.|Biochem Pharmacol. 2019 Nov;169:113608.|Bioengineering (Basel) . 2023 Jun 9;10 (6) :702.|bioRxiv. 2024 Mar 13.|Cell Rep Methods. 2024 May 8:100777.|Clin Sci. 2023 Jan 13;137 (1) :109-127.|Dev Cell. 2020 Dec 21;55 (6) :679-694.e11.|eNeuro. 2025 Jan 9:ENEURO.0347-24.2024.|Exp Cell Res. 2022 Nov 11;422 (1) :113416.|Exp Ther Med. 2020 Mar;19 (3) :1701-1710.|J Appl Polym Sci. 2024 Sep 25.|J Cell Physiol. 2020 Jul;235 (7-8) :5811-5822.|J Inflamm Res. 2024 Nov 19:17:8945-8964.|Microb Pathog. 2024 Sep 21:106960.|Neoplasia. 2024 Dec 30:60:101096.|Patent. US20180263995A1.|PLoS One. 2024 Jan 5;19 (1) :e0287206.|SSRN. 2024 Mar 26.|Stem Cell Res Ther. 2024 Oct 8;15 (1) :350.|Stem Cells Transl Med. 2021 May;10 (5) :743-755.|Toxicon. 2026 Jan:269:108660.

Related Products

CatalogName
HY-15825GIWP L6 (GMP)
HY-13912-01IWP-2
HY-121540IWP-2-V2
HY-117443IWP-051
HY-15825-01IWP L6
HY-12879-01IWP-4
HY-107570-01IWP-12
HY-100536-01IWP-3
HY-100853-01IWP-O1
HY-1715202'-O-MOE-GMP

Alternative Products

CatalogName
BLG-G022-102′-GMP
317615-01GMP reductase 2 (GMPR2)
481943GMPR2 (GMP Reductase 2)
MF-0054983-012'-O-MOE-GMP
MBS256228-01Guanosine- 2'- O- monophosphate (2'-GMP)
PR15125CFIL-2 (Interleukin-2) GMP, CF
PCH90024GMP Recombinant Human IL-2
300-950-050GMP Human IL-2 (c126s)
GMP-L02H14-1106IUGMP Human IL-2 Protein
BLG-A170-252′-/3′-AEC-5′-GMP

Popular Products